Prostate cancer is the most common cancer in men in the UK. Naturally, this statistic causes significant anxiety, leading many men to seek out Prostate-Specific Antigen (PSA) testing. However, the PSA test is frequently misunderstood. It is a powerful tool in the clinical arsenal, but it is not a simple "yes or no" test for cancer. Understanding what PSA is, and what it isn't, is crucial for making informed decisions about your health.
As a clinician, I spend a great deal of time counseling patients on PSA results. The most important fact to establish is this: PSA is a protein produced by both normal and malignant cells of the prostate gland. It is normal to have a small amount of PSA in your blood. An elevated PSA level indicates that there is an issue with the prostate, but it does not automatically mean cancer.
Causes of an Elevated PSA
While prostate cancer can cause PSA levels to rise, several benign (non-cancerous) conditions are far more common culprits:
- Benign Prostatic Hyperplasia (BPH): This is a non-cancerous enlargement of the prostate gland, incredibly common as men age. A larger prostate naturally produces more PSA.
- Prostatitis: Inflammation or infection of the prostate gland can cause a sharp, temporary spike in PSA levels.
- Physical Stimulation: Recent ejaculation, vigorous exercise (particularly cycling, which puts pressure on the perineum), or a recent digital rectal exam (DRE) can temporarily elevate PSA.
- Urinary Tract Infections (UTIs): Infections in the urinary tract can irritate the prostate and raise PSA.
Interpreting the Numbers: Age-Specific Ranges
Because the prostate naturally enlarges with age, what is considered a "normal" PSA level increases as you get older. A PSA level of 3.0 ng/mL might be considered elevated for a 45-year-old man but perfectly normal for a 75-year-old. Clinical guidelines use age-adjusted reference ranges to improve the accuracy of screening and reduce unnecessary biopsies.

The Concept of PSA Velocity
A single PSA reading provides a snapshot, but monitoring PSA over time—known as PSA velocity—often provides much more valuable clinical insight. If a man's PSA is slightly elevated but remains stable over several years, it is highly likely due to benign enlargement (BPH). However, if the PSA level is rising rapidly year over year, even if it is still within the "normal" range, it warrants urgent urological investigation, as rapid growth is a hallmark of malignancy.
Free vs. Total PSA
If a Total PSA test comes back elevated, a secondary test measuring "Free PSA" can provide further clarity. PSA circulates in the blood in two forms: bound to proteins and unbound (free). Studies have shown that men with prostate cancer tend to have a lower percentage of Free PSA compared to men with benign conditions like BPH. A Free PSA ratio can help clinicians determine the likelihood of cancer and whether a biopsy is necessary.
Making an Informed Decision
The decision to undergo PSA screening should be a shared one between you and your healthcare provider, weighing your age, family history, and personal risk factors. For men over 50 (or over 45 with a family history of prostate cancer or of Black African/Caribbean descent), establishing a baseline PSA is a prudent step in proactive health management.
An elevated PSA is not a reason to panic; it is a signal to investigate further. By understanding the nuances of the test, you can approach prostate health with clarity rather than fear.
Check Your Prostate Health
Establishing a baseline PSA is one of the most important proactive steps men can take as they approach their 50s:
- PSA (Prostate Specific Antigen) Blood Test Kit: A simple home blood test measuring Total PSA — ideal for establishing a baseline and tracking PSA velocity over time.
Medical References
- National Institute for Health and Care Excellence (NICE). (2021). Prostate cancer: diagnosis and management. NICE guideline [NG131].
- Prostate Cancer UK. (2023). The PSA test.
- Catalona, W. J., et al. (1998). Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. JAMA, 279(19), 1542-1547.
